ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0264 • ACR Convergence 2020

    Prevalence and Risk Factors Associated with Isolated Neutropenia in Outpatients with Systemic Lupus Erythematosus

    Nouf Alhammadi1, Murray Urowitz2 and Dafna Gladman3, 1University of Toronto, Toronto, Canada, 2University Health Network, University of Toronto, Toronto, ON, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Leukopenia in SLE is defined as leukocyte count below 4,000/mm3 on two or more occasions according to the ACR criteria and may include a…
  • Abstract Number: 0265 • ACR Convergence 2020

    Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort

    Elena Elefante1, Chiara Tani2, Viola Signorini2, Virginia Poli2, Chiara Stagnaro2, Alice Parma2, Dina Zucchi2, Linda Carli2, Francesco Ferro2, Anca Askanase3 and Marta Mosca2, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa; Department of Medical Biotechnology, University of Siena, Pisa, Italy, 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 3Columbia University College of Physicians & Surgeons, New York, NY

    Background/Purpose: Multiple indices are available to measure disease activity in SLE patients, but are often considered too complex and time consuming for use in routine…
  • Abstract Number: 0266 • ACR Convergence 2020

    The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus

    Cigdem Cetin1, Tugba Sarac Sivrikoz1, Muge Ates Tıkız1, Ege Sinan Torun1, Sibel Zarali1, Yasemin Yalcinkaya1, Ahmet Gül1, Murat İnanç1, Mahdume Lale Öcal2, İbrahim Kalelioğlu1 and Bahar Artim Esen1, 1İstanbul Faculty of Medicine, İstanbul, Turkey, 2Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) can present with acute disease flares/exacerbations during pregnancy and postpartum period1. These flares can cause adverse pregnancy outcomes…
  • Abstract Number: 0267 • ACR Convergence 2020

    Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?

    Beatriz Tejera Segura1, Irene Altabás González2, Iñigo Rúa-Figueroa3, Natalia Pérez Veiga4, Victor del Campo Pérez5, Alejandro Olivé-Marqués6, Maria Galindo-Izquierdo7, Jaime Calvo-Alén8, Juan Ovalles-Bonilla9, Antonio Fernandez-Nebro10, Raul Menor Almagro11, Eva Tomero Muriel12, N. Del-val-del-amo13, Maria Esther Uriarte14, VM Martínez Taboada15, Jose Luis Andreu Sanchez16, Alina Lucica Boteanu17, Francisco Javier Narváez18, A Morasat19, Carlos Montilla Morales20, JM Senabre Gallego21, Blanca Hernández Cruz22, Mariano Andrés23, Eva Salgado Pérez24, Mercedes Freire-González25, Sergio Ramon Machin Garcia1, Clara Moriano26, Lorena Expósito27, Clara E. Perez-Velasquez28, ML Velloso-Feijoo29, Ana Paula Cacheda30, Nuria Lozano Rivas31, Gema Bonilla32, Marta Arévalo33, Inmaculada Jimenez34, VE Quevedo-Vila35, Francisco Manero-Ruiz36, Paloma García de la Peña37, TR Vázquez-Rodríguez38, J Ibáñez-Ruan39, Tatiana Cobo-Ibañez40 and Jose Maria Pego-Reigosa41, 1Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 2Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, 4Grupo IRIDIS, Universidad de Vigo, Vigo, Pontevedra, 5Hospital Universitario Meixoeiro, Vigo, Vigo, Pontevedra, Spain, 6Hospital Germans Trias i Pujol, Barcelona, Spain, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, 9Hospital General Universitario Gregorio Marañón, Madrid, Spain, 10University of Malaga, Malaga, Spain, 11Hospital General Universitario de Jerez de la Frontera, Puerto De Santa Mar�a, Spain, 12Hospital Universitario de la Princesa, Madrid, Madrid, Spain, 13Complejo Hospitalario de Navarra, Pamplona, Spain, 14Hospital Universitario Donostia, San Sebastian, Spain, 15Hospital Universitario Marqués de Valdecilla, Santander, Spain, 16Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 17PRINTO, Istituto Giannina Gaslini, Genova, Italy, 18Hospital Bellvitge, BARCELONA, Spain, 19Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, 20Hospital Universitario de Salamanca, Salamanca, Spain, 21Hospital Marina Baixa, Alicante, Spain, 22Universidad de Sevilla, Sevilla, Spain, 23Hospital General Universitario de Alicante, Alicante, Spain, 24Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 25CHU Coruña, Coruña, Spain, 26Complejo Asistencial Universitario de León, León, Spain, 27Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 28Basurto University Hospital, Bilbao, Spain, 29Hospital Universitario de Valme, Sevilla, Spain, 30Hospital son LLátzer, Palma de Mallorca, Spain, 31Hospital Clínico Universitario Virgen de Arrixaca, Murcia, Spain, 32Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, 33Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, 34Hospital Clínico San Ceciio Granada, Granada, Spain, 35Hospital Comarcal de Monforte, Lugo, Spain, 36Hospital Universitario Miguel Servet, Zaragoza, Spain, 37Hospital HM, Madrid, Spain, 38Hospital Universitario Lucus Augusti, Lugo, Spain, 39Hospital Povisa, Vigo, Pontevedra, Spain, 40Hospital Infanta Sofia, Madrid, Spain, 41University Hospital of Vigo, Galicia Sur Health Research Institute, Vigo, Spain

    Background/Purpose: To describe the GI manifestations of SLE in the RELESSER (Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology) cohort and…
  • Abstract Number: 0268 • ACR Convergence 2020

    Impact of Flares on Healthcare Resource Usage and PROs in Systemic Lupus Erythematosus Patients

    Zahi Touma1, Benjamin Hoskin2, Christian Atkinson2, David Bell3, James Pike2, Jennifer Lofland4, Pamela Berry5, Chetan Karyekar5 and Karen Costenbader6, 1University of Toronto, Toronto, ON, Canada, 2ADELPHI REAL WORLD, Bollington, United Kingdom, 3ADELPHI REAL WORLD, Bollington, Macclesfield, United Kingdom, 4Janssen Global Market Access, horsham, PA, 5Janssen Global Services, LLC, Horsham, PA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: The effect of flares on healthcare resource usage and patient-reported outcome scores in SLE patients is not well quantified.To understand how flares impact healthcare…
  • Abstract Number: 0269 • ACR Convergence 2020

    Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality

    Ehizogie Edigin1, Precious Eseaton2, Pius Ojemolon3 and Augustine Manadan4, 1John H Stroger Jr. Hospital of Cook County, Chicago, IL, 2University of Benin Teaching Hospital, Benin, 3St. George's University, St. George's, Grenada, 4Cook County Hospital/Rush University Medical center, Chicago, IL

    Background/Purpose: Libman-Sacks endocarditis characterized by thrombotic and/or non-infective sterile inflammatory vegetations are common in Systemic Lupus Erythematosus (SLE) and associated with increased morbidity. These vegetations…
  • Abstract Number: 0270 • ACR Convergence 2020

    The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE

    Laura Whittall-Garcia1, Dafna Gladman2, Murray Urowitz3, Jiandong Su4 and Sindhu Johnson5, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada

    Background/Purpose: SLE is characterized by different patterns of disease activity throughout its course. Overall, a higher disease activity is an important predictor of mortality and…
  • Abstract Number: 0271 • ACR Convergence 2020

    External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus

    Alicia Malone1, Alexandra Legge1 and John Hanly1, 1Dalhousie University, Halifax, NS, Canada

    Background/Purpose: Using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, a frailty index (FI) was recently developed as a measure of susceptibility…
  • Abstract Number: 0272 • ACR Convergence 2020

    Superior Discrimination Between LLDAS and DORIS Remission with Modification of Prednisolone Dose Threshold

    Eric Morand1, Vera Golder2, Worawit Louthrenoo3, Shue Fen Luo4, Yeong-Jian Wu5, Aisha Lateef6, Sargunan Sockalingam7, Sandra Navarra8, Leonid Zamora9, Laniyati Hamijoyo10, Yasuhiro Katsumata11, Masayoshi Harigai12, Madelynn Chan13, Sean O'Neill14, Fiona Goldblatt15, Yi-Hsing Chen16, Yanjie Hao17, Zhuoli Zhang17, Jun Kikuchi18, Tsutomu Takeuchi19, Chak Sing Lau20, Zhanguo Li21, Alberta Hoi22, Mandana Nikpour23 and Rangi Kandane-Rathnayake2, 1Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 2Monash University, Clayton, Victoria, Australia, 3Chiang Mai University Hospital, Muang, Thailand, 4Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), 5Chang Gung Memorial Hospital, Guishan, Taiwan (Republic of China), 6National University Hospital, Singapore, Singapore, 7University of Malaya, Kuala Lumpur, Malaysia, 8University of Santo Tomas, Manila, Philippines, 9University of Santo Thomas, Manila, Philippines, 10University of Padjadjaran, Bandung, Indonesia, 11Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 12Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 13Tan Tock Seng Hospital, Singapore, Singapore, 14Sydney University, Sydney, Australia, 15Royal Adelaide Hospital, Adelaide, Australia, 16Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 17Peking University First Hospital, Beijing, China (People's Republic), 18Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 19Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, 20Hong Kong University, Hong Kong, Hong Kong, 21Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), 22Monash University, Melbourne, Victoria, Australia, 23The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia

    Background/Purpose: Treat-to-target (T2T) approaches to rheumatic disease require the definition and validation of low disease activity and remission endpoints that should be concentrically more stringent.…
  • Abstract Number: 0273 • ACR Convergence 2020

    Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia

    Jennifer Rogers1, Megan Clowse2, Lisa Criscione-Schreiber3, Jayanth Doss4, Rebecca Sadun4, Kai Sun5 and Amanda Eudy4, 1Duke, Durham, NC, 2Duke University, Chapel Hill, NC, 3Duke University School of Medicine, Durham, NC, 4Duke University, Durham, NC, 5Duke University Hospital, Durham

    Background/Purpose: Patients with SLE have poor health related quality of life (HRQoL), however the differences in the predominant causes of decreased HRQoL across subgroups of…
  • Abstract Number: 0274 • ACR Convergence 2020

    The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades

    Mehmet Hocaoglu1, Shirley-Ann Osei-Onomah2, Jesse Dabit3, Rachel Giblon3, Thomas O'Byrne3, Fernando C. Fervenza3, Cynthia Crowson4 and Ali Duarte-Garcia3, 1University of Maryland Medical Center Midtown Campus, Baltimore, MD, 2Mayo Clinic, Rochester, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Estimating the incidence of lupus nephritis (LN) is important to understand disease burden, particularly since patients with LN have a higher morbidity and mortality…
  • Abstract Number: 0275 • ACR Convergence 2020

    Paradoxical Relationship Between Disease Activity and Satisfaction with Care in Lupus

    Sana Afroz1, Ailda Nika2, Winston Sequeira3, Joel Block4, Patricia Katz5 and Meenakshi Jolly2, 1RUMC, chicago, IL, 2Rush University, Chicago, IL, 3Rush University Medical Center, Oak Brook, IL, 4Rush University Medical Center, Chicago, 5University of California, San Francisco, Novato, CA

    Background/Purpose: Satisfaction with care (SC) is increasingly being used as a surrogate of QOC, with growing emphasis on optimizing SC/patient experience in health care. We…
  • Abstract Number: 0276 • ACR Convergence 2020

    Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy

    Raeann Whitney1, Amanda Eudy2, Cynthia Coffman3, Megan Clowse4, Lisa Criscione-Schreiber5, Jayanth Doss2, Rebecca Sadun2, Kai Sun2 and Jennifer Rogers6, 1Duke University Medical Center, Durham, NC, 2Duke University, Durham, NC, 3Duke University, Durham, 4Duke University, Chapel Hill, NC, 5Duke University School of Medicine, Durham, NC, 6Duke, Durham, NC

    Background/Purpose: Management of Type 2 SLE (widespread pain, fatigue, depression, sleep distrubance, and cognitive dysfunction) is challenging and often requires multiple medications to ameliorate symptoms.…
  • Abstract Number: 0277 • ACR Convergence 2020

    Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria

    Ali Duarte-Garcia1, Mehmet Hocaoglu2, Shirley-Ann Osei-Onomah3, Jesse Dabit1, Rachel Giblon1 and Cynthia Crowson4, 1Mayo Clinic, Rochester, MN, 2University of Maryland Medical Center Midtown Campus, Baltimore, MD, 3Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Classification criteria are standardized definitions required to identify well defined cohorts of patients for research. In practice they are also used as a framework…
  • Abstract Number: 0278 • ACR Convergence 2020

    Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study

    Mehmet Hocaoglu1, Mark Denis P. Davis2, Shirley-Ann Osei-Onomah3, Jesse Dabit2, Rachel Giblon2, Thomas O'Byrne2, Cynthia Crowson4 and Ali Duarte-Garcia2, 1University of Maryland Medical Center Midtown Campus, Baltimore, MD, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous chronic disease with potential for long lasting morbidity. Studies that provide incidence data on the entire spectrum…
  • « Previous Page
  • 1
  • …
  • 852
  • 853
  • 854
  • 855
  • 856
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology